Technical Analysis for ALBT - Avalon GloboCare Corp.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Fell Below 20 DMA | Bearish | -6.07% | |
| Wide Bands | Range Expansion | -6.07% | |
| NR7 | Range Contraction | -11.71% | |
| Narrow Range Bar | Range Contraction | -11.71% | |
| Upper Bollinger Band Walk | Strength | -11.71% | |
| Wide Bands | Range Expansion | -11.71% | |
| Fell Below 50 DMA | Bearish | -10.64% | |
| Volume Surge | Other | -10.64% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 21 hours ago |
| Down 5% | about 21 hours ago |
| Fell Below Previous Day's Low | about 21 hours ago |
| Down 10% | about 21 hours ago |
| 20 DMA Resistance | about 22 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 10/11/2024
Avalon GloboCare Corp. is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics.
Sector: Healthcare
Industry: Medical Care
Keywords: Medicine Clinical Medicine Immunotherapy Cell Therapy Exosome Bioproduction Vesicles
Classification
Sector: Healthcare
Industry: Medical Care
Keywords: Medicine Clinical Medicine Immunotherapy Cell Therapy Exosome Bioproduction Vesicles
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 21.6 |
| 52 Week Low | 2.424 |
| Average Volume | 124,491 |
| 200-Day Moving Average | 5.13 |
| 50-Day Moving Average | 3.51 |
| 20-Day Moving Average | 3.18 |
| 10-Day Moving Average | 3.25 |
| Average True Range | 0.61 |
| RSI (14) | 37.11 |
| ADX | 23.68 |
| +DI | 22.16 |
| -DI | 29.38 |
| Chandelier Exit (Long, 3 ATRs) | 2.77 |
| Chandelier Exit (Short, 3 ATRs) | 4.26 |
| Upper Bollinger Bands | 3.84 |
| Lower Bollinger Band | 2.53 |
| Percent B (%b) | 0.31 |
| BandWidth | 41.06 |
| MACD Line | -0.07 |
| MACD Signal Line | -0.11 |
| MACD Histogram | 0.0371 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.81 | ||||
| Resistance 3 (R3) | 3.83 | 3.55 | 3.67 | ||
| Resistance 2 (R2) | 3.55 | 3.33 | 3.55 | 3.62 | |
| Resistance 1 (R1) | 3.25 | 3.19 | 3.11 | 3.23 | 3.57 |
| Pivot Point | 2.97 | 2.97 | 2.91 | 2.97 | 2.97 |
| Support 1 (S1) | 2.67 | 2.75 | 2.53 | 2.65 | 2.31 |
| Support 2 (S2) | 2.39 | 2.61 | 2.39 | 2.26 | |
| Support 3 (S3) | 2.09 | 2.39 | 2.22 | ||
| Support 4 (S4) | 2.07 |
